849 results about "Monoclinic crystal system" patented technology

A perovskite type oxide of a single crystal structure or a uniaxial-oriented crystal structure represented by ABO3 where site A includes Pb as a main component and site B includes a plurality of elements, wherein the perovskite type oxide includes a plurality of crystal phases selected from the group consisting of tetragonal, rhombohedral, orthorhombic, cubic, pseudo-cubic and monoclinic systems and the plurality of crystal phases are oriented in the direction of <100>.

The invention includes a plasma etch-resistant film for a substrate comprising a yttria material wherein at least a portion of the yttria material is in a crystal phase having a crystal lattice structure, wherein at least 50% of the yttria material is in a form of a monoclinic crystal system. The film may be treated by exposure to a fluorine gas plasma. Also included are plasma etch-resistant articles that include a substrate and a film, wherein the film comprises an yttria material and at least a portion of the yttria material is present in the film in a crystal phase having a crystal lattice structure and at least 50% of the yttria material is in a form of a monoclinic crystal system. Several methods are contemplated within the scope of the invention.

A photocatalytic material containing tungsten trioxide fine particles having an average particle diameter of 0.5 μm or smaller and a crystal structure of a monoclinic crystal system as a main component.

The present invention provides a lithium composite metal oxide containing Li and at least one transition metal element, wherein at least one lithium composite metal oxide particle constituting the lithium composite metal oxide has both hexagonal and monoclinic crystal structures. Further, the present invention also provides a lithium composite metal oxide containing Li, Ni and M (where, M represents one or more kinds of transition metal elements selected from the group consisting of Mn, Co and Fe), having a diffraction peak (diffraction peak A) at an angle 2θ in a range from 20° to 23° in a powder X-ray diffraction pattern of a lithium composite metal oxide which is obtained by powder X-ray diffraction measurement made in the condition that CuKα is used as a radiation source and the measurement range of diffraction angle 2θ is in a range from 10° to 90°.

The invention discloses a nano copper oxide analogue enzyme and a method for measuring hydrogen peroxide by using the nano copper oxide analogue enzyme as a peroxide analogue enzyme. The nano copper oxide analogue enzyme is nano copper oxide powder with a grain diameter ranging from 5 to 8 nanometers; the nano copper oxide is Cuo of a monoclinic system, the space group is C2 / c; and the maximum absorption peaks of the typical ultraviolet-visible absorption spectra of the prepared nano copper oxide are at 280-nanometer positions. The nano copper oxide analogue enzyme is obtained by a chemical precipitation process. The nano copper oxide analogue enzyme has a catalytic property similar to that of peroxidase. When the nano copper oxide analogue enzyme is used in a 4-aminoantipyrine-ol system, the colorimetric detection of hydrogen peroxide can be realized, the hydrogen peroxide detection limit is 0.02mmol / L, and the linear range is 1mmol / L.

The invention belongs to the technical field of high-performance medical alloy materials and particularly relates to a medical zirconium alloy high in surface wear resistance and integral tenacity and a preparation method and application thereof. The surface of the medical zirconium alloy is provided with a micron-level thick oxide ceramic layer is mainly composed of nonoclinic-system zirconia and a small amount of tetragonal-system zirconia; the matrix of the medical zirconium alloy is zirconium alloy, which is specifically composed of, by weight percentage, 76.5-100 wt.% of Zr, 0-19 wt.% of Nb, 0-4.5 wt.% of Hf and inevitable trace impurities as balance; an oxygen-enriched transition layer is arranged between the oxide ceramic layer and the matrix alloy, namely, oxygen is dissolved inside the matrix to form zirconium-oxygen solid solution. The high-wear-resistance and high-tenacity medical zirconium alloy combines the plastic deformation technology and the high-temperature oxidation technology and greatly improves the surface hardness, the wear resistance and the alloy strength, thereby having a broad application prospect in biomedicine, particularly in the aspect of biomedical implants.

A method for producing a zirconia-layered orthopedic implant component includes depositing zirconium onto the orthopedic implant component, thereby forming a zirconium-layered component, and converting at least a portion of the zirconium into a substantially monoclinic zirconia surface layer unaccompanied by a substantial underlying α-phase. A method for producing a zirconia-layered orthopedic implant component includes depositing zirconium onto the orthopedic implant component by ion bombardment and deposition in a vacuum to form a zirconium-layered component including an intermix zone at least 1000 Å thick and a zirconium layer about 3-5 μm thick, and heat treating the zirconium-layered component at a temperature of about 500-600° C. in an atmosphere containing oxygen.

The invention relates to a preparation method for a bismuth vanadate composite photocatalyst loaded with strontium ferrite, and belongs to the field of inorganic catalytic materials. According to the preparation method, bismuth vanadate adopts the structure of scheelite in the monoclinic system; while the degradation rate, of the composite photocatalyst loaded with the strontium ferrite, for methylene blue can reach 93 percent in 5h, the degradation rate, of a similar composite photocatalyst of bismuth vanadate loaded with ferroferric oxide, for the methylene blue can reach 80 percent in 8 h. Moreover, the prepared composite photocatalyst has photocatalysis activity in relatively-wide wavelength range, and can efficiently and cyclically degrade organic pollutants in heteroaromatic dye-type wastewater under the irradiation of ultraviolet light, visible light and natural light through photocatalysis. Meanwhile, the composite catalyst is convenient to recover with the recovery rate not less than 92 percent; the degradation rate, of the recovered composite catalyst, for the methylene blue can reach 60 percent in 5h. The preparation method is simple and has an excellent application prospect.

A piezoelectric material, characterized in that a main component of the piezoelectric substance is PZT which has perovskite type structure expressed in Pb(ZrxTi1-x)O3 (1) (x expresses an element ratio Zr / (Zr+Ti) of Zr and Ti in the formula), an element ratio Pb / (Zr+Ti) of Pb, Zr and Ti of the piezoelectric substance is 1.05 or more, and an element ratio Zr / (Zr+Ti) of Zr and Ti is 0.5 to 0.8 inclusive, and the piezoelectric substance has at least a perovskite type structure of monoclinic system.

A subject for the invention relates to providing a positive active material for lithium ion secondary batteries which attains a high discharge capacity and is excellent in rate characteristics and cycle characteristics. A feature of the invention resides in that a lithium-nickel-manganese composite oxide which has a composition represented by LixNiyMnzO2 wherein x is 1+1 / 9±(1+1 / 9) / 10, y is 4 / 9±(4 / 9) / 10, and z is 4 / 9±(4 / 9) / 10, in particular, represented by the general formula Li[Ni0.5-0.5XMn0.5-0.5XLiX]O2 wherein X satisfies 0.05≦X≦0.11, and has a crystal structure belonging to the monoclinic system and having a space group of C12 / ml (No. 12) is used as a positive-electrode material. The lithium-nickel-manganese composite oxide preferably is one in which in X-ray powder diffractometry using a Cu—Kα ray, the peak intensity ratio I(002) / I(13-3) between the (002) plane and the (13-3) plane in terms of Miller indexes hkl on the assumption of belonging to C12 / ml (No. 12) of the monoclinic system is 1.35 or higher.

A cathode composite material includes a cathode active material and a coating layer coated on a surface of the cathode active material. The cathode active material includes a layered type lithium nickel cobalt manganese oxide. The coating layer comprises a lithium metal oxide having a crystal structure belonging to C2 / c space group of the monoclinic crystal system. The present disclosure also relates to a lithium ion battery including the cathode composite material.

The invention relates to a vanadate nanofiber photocatalyst and a preparation method thereof. The nanofiber photocatalyst is pucherite, or silver vanadate, or a compound of pucherite and silver vanadate. Organic vanadic salt, organic bismuth salt and the like with good alcohol solubility are taken as precursor reactors, a spinning solution is prepared by a PVP (Polyvinyl Pyrrolidone) and alcohol system, electrospining is performed by an electrospining device, then high-temperature roasting is performed, and the vanadate nanofiber photocatalyst is obtained. A prepared vanadate nanofiber is in a monoclinic crystal phase, is 30-100nm in diameter, has a narrower band gap, shows good visible light catalytic degradation ability for ofloxacin, a contaminant in water, and can be separated from a solution quickly by precipitation.

A cathode composite material includes a cathode active material and a coating layer coated on a surface of the cathode active material. A material of the coating layer is a lithium metal oxide having a crystal structure belonging to C2 / c space group of the monoclinic crystal system. The present disclosure also relates to a lithium ion battery including the cathode composite material.

The invention relates to a method for preparing monoclinic crystal system crystalline copper oxide and an application of the monoclinic crystal system crystalline copper oxide. The method comprises the following steps: a. a sodium hydroxide or potassium hydroxide water solution with a concentration of between 5 and 50 percent and a volume of between 30 and 80 percent of the volume of a reaction vessel is added into the reaction vessel, preheated to between 30 and 100 DEG C, added with crystalline copper chloride hydroxide with the addition between 1 / 6 and 1 / 3 of the mol number of sodium hydroxide, and reacted for 10 to 60 minutes at a reaction temperature of between 30 and 100 DEG C and under the condition of stirring; b. crystalline copper oxide is prepared after washing, pumping filtration, centrifugation and drying of reacted materials; and c. the crystalline copper oxide is crushed by the physical method, and the activated copper oxide with fine granularity are prepared. The method is easy to realize separation of the copper chloride hydroxide and the copper oxide with other water-soluble background salts, and has a simple technique and low production cost; and the crystalline copper oxide prepared has high yield, high purity, high activity, good quality and is suitable for mass production.

A cathode composite material includes a cathode active material and a coating layer coated on a surface of the cathode active material. The cathode active material includes a lithium cobalt oxide. The coating layer includes a lithium metal oxide having a crystal structure belonging to C2 / c space group of the monoclinic crystal system. The present disclosure also relates to a lithium ion battery including the cathode composite material.

The invention discloses a cyclodextrin metal-organic framework compound and its preparation method and use. The cyclodextrin metal-organic framework compound has a chemical formula of Na(C42H64O35). 11H2O (Na-CD-MOF), is a monoclinic crystal and has a P2<1> space group and cell parameters of a=15.2372(5)A, b=10.5956(5)A, c=20.2018(5)A, alpha=Y=90.0371, beta=108.2235 degrees and V=3097.91719A<3>. The crystal has a white color and comprises one beta-cyclodextrin, one Na<+> ion and eleven crystal water molecules. The invention prepares the novel degradable Na-beta-cyclodextrin metal-organic framework molecule without toxic or side effect on the human body. Through a grinding method, the ASP-Na-CD-MOF clathrate is prepared.

The invention discloses a compound barium borofluoride, a barium borofluoride non-linear optical crystal, and a preparation method and a use of the barium borofluoride non-linear optical crystal. The compound barium borofluoride and the barium borofluoride non-linear optical crystal have the same chemical formula of Ba3B6O11F2. The barium borofluoride non-linear optical crystal belongs to a monoclinic system, has a space group P2(1), has cell parameters shown in the patent specification, wherein beta is equal to 101.351(4)deg., and has the molecular weight of 690.88. The powder frequency-doubling effect of the barium borofluoride non-linear optical crystal is 3 times that of KDP (KH2PO4). The compound barium borofluoride is synthesized by a solid-phase reaction method. The barium borofluoride non-linear optical crystal grows by a high-temperature melting method. The barium borofluoride non-linear optical crystal has large mechanical hardness, can be cut, polished and stored easily, and can be widely used in preparation of nonlinear optical devices such as a frequency multiplication generator, an upper frequency converter, a lower frequency converter and an optical parameter resonator.

A piezoelectric film element is provided, which is capable of improving piezoelectric properties, having on a substrate at least a lower electrode, a lead-free piezoelectric film, and an upper electrode, wherein at least the lower electrode out of the lower electrode and the upper electrode has a crystal structure of a cubic crystal system, a tetragonal crystal system, an orthorhombic crystal system, a hexagonal crystal system, a monoclinic crystal system, a triclinic crystal system, a trigonal crystal system, or has a composition in which one of these crystals exists or two or more of them coexist, and crystal axes of the crystal structure are preferentially oriented to a specific axis smaller than or equal to two axes of these crystals, and a ratio c / a′ is set in a range of 0.992 or more and 0.999 or less, which is the ratio of a crystal lattice spacing c in a direction of a normal line to the substrate surface, with respect to a crystal lattice spacing a′ whose inclination angle from the substrate surface is in a range of 10° or more and 30° or less.

An actuator device includes: a layer provided on a single crystal silicon (Si) substrate, and made of silicon dioxide (SiO2); at least one buffer layer provided on the layer made of silicon dioxide (SiO2); a base layer provided on the buffer layer, and made of lanthanum nickel oxide (LNO) having the (100m) plane orientation; and a piezoelectric element. The piezoelectric element includes: a lower electrode provided on the base layer, and made of platinum (Pt) having the (100) plane orientation; a piezoelectric layer made of a ferroelectric layer whose plane orientation is the (100) orientation, the piezoelectric layer formed on the lower electrode by epitaxial growth where a crystal system of at least one kind selected from a group consisting of a tetragonal system, a monoclinic system and a rhombohedral system dominates the other crystal systems; and an upper electrode provided on the piezoelectric layer.

The invention belongs to the technical field of chemical compound preparation and in particular provides a novel metal organic framework structured compound and a preparation method thereof. The structural formula of the compound is [Zn4(mu4-O)(BTC)2(phen)2].4H2O, wherein mu4 is oxo-bridged; BTC is 1,3,5-trimesic acid (C9H6O6); phen is 1,10-o-phenanthroline (C12H8N2); the molecular formula of the compound is C42H30N4O17Zn4 and the molecular weight is 1124.18; the compound belongs to the monoclinic system and C2 / c space group; the cell parameter beta is 92.353(3) degrees; the cell volume is shown in the specification, Z is 4 and Dc is 1.806g / cm3. In the method, the cheap and nontoxic zinc acetate or zinc chloride is used as the reactant and the organics trimesic acid and o-phenanthroline are used as the ligands to obtain the Zn-MOFs material. The compound has simple preparation process and equipment and high heat stability at the temperature of more than 450 DEG C and can be widely applied to fluorescent organism markers.

The invention relates the method for preparation of pucherite composite photocatalyst loaded on cobalt oxide. The photocatalyst comprises semi-conductor pucherite particle and cobalt oxide particle. The pucherite is monoclinic crystal system scheelite structure, and the diameter is 100nm-5mum. The grain diameter of cobalt oxide is 10nm-1mum. The mass ratio of cobalt oxide and pucherite is 1-100mg / g. The specific surface area of composite photocatalyst is 0.5-5m2 / g. The said photocatalyst can effectively degrade the noxious and harmful chemical under the ultraviolet light, visible light and natural light radiating. And the photocatalyst is easy to separate and recover.

The invention discloses a white light LED, an enhanced light transfer powder, a phosphor powder and a method of producing phosphor powder that use a plurality of radiating color lights and include a white light nitride heterostructure. The invention provides a novel solid liquid of a luminescence material with a chemical formula BaαY3βAl2α+5βO4α+12β, where α and β have a value ranging 0.1˜4. The crystal lattice structure of the phosphor powder varies from cubic crystal system to monoclinic crystal system accroding to the change of the ratio of α and β. It shows significant yellow color and yellowish orange color and has very high quantum light emitting efficiency and enduring light emitting time. In such novel phosphor powder base, the invention further develops an enhanced light transfer apparatus that is a blue light heterostructure emiting a raidaion with a wavelength λ=450˜475 nm and comprised of polymers and phosphor powder particles filled therein, and the concentration of phosphor powder is 1%˜50%. The novel white semiconductor source has a very high light intensity (I>100 cd) and luminous flux, and its light emitting efficiency is up to 501 m / w.

A rare earth-based core for use in the casting of a reactive metal is described. The core contains a ceramic composition which includes at least about 10% by weight of monoclinic rare earth aluminate (RE4Al2O9), wherein RE represents at least one rare earth element; and at least about 10% by weight of at least one free rare earth oxide. The ceramic phase of the composition may include a microstructure which comprises a multitude of substantially spherical pores which are formed as a result of the removal of aluminum metal from the core composition during a heat treatment step. Additional embodiments relate to a method for the fabrication of a ceramic core, employing a rare earth oxide, aluminum metal, and a binder. Methods for removing cores from a cast part are also described.

This invention discloses a method for preparing BaTeMo2O9 crystal and its application. The crystal belongs to monoclinic system, and the space group is P21. The method comprises: adding BaTeMo2O9 polycrystalline powder into appropriate fluxing agent system (TeO2-MoO3, MoO3, TeO2, B2O3 or PbO-B2O3), placing in a Pt crucible, heating to melt the raw materials, mixing adequately, cooling to the melt saturation point, adding seed crystals, and growing homogeneous nonlinear optical BaTeMo2O9 single crystal with lengths exceeding 10 mm and thickness exceeding 5 mm. The obtained BaTeMo2O9 single crystal has strong frequency multiplification effect and IR absorption edge greater than 5000 nm, and has such advantages as high stability, no decomposition at room temperature, and no deliquescence. The crystal has nonlinear optical, electro-optical and piezoelectric applications. The method has such advantages as easy operation,and abundant raw materials.

The invention belongs to the technical field of photocatalyst materials and preparation thereof, and aims to provide a method for preparing a mesoporous beta-Ga2O3 nanorod photocatalyst by using PEG (polyethylene glycol) as a template. According to the method, gallium-containing compounds and alkaline matters are used as raw materials, the PEG is used as the template, and a hydrothermal synthesis method is adopted to prepare the mesoporous beta-Ga2O3 nanorod photocatalyst. The invention can effectively control the crystal growth, improve the crystal form structure of the catalyst, increase the specific area of the catalyst, generate abundant oxygen vacancies or gallium-oxygen vacancy pairs, and enhance the photoresponse intensity of the catalyst, thereby enhancing the photocatalytic efficiency of the catalyst. The experiment of decomposing methylbenzene by photocatalytic oxidation indicates that the photocatalytic efficiency of the PEG-modified beta-Ga2O3 is 1.2-10 times of that of the beta-Ga2O3 which is not modified by the PEG. The method has the advantages of simple technique and adjustable parameters, and is easy to operate; and the prepared beta-Ga2O3 nanorod photocatalyst is a monoclinic system with complete and regular crystal form, belongs to a mesoporous material, and has the advantages of high photoresponse capacity and high catalytic performance.

The invention provides a levamlodipine besylate crystal with the molecular formula being (C20H25ClN2O5) (C6H6O3S) (H2O) 1.5 and the molecular weight being 594.07. Crystallography measurement parameters are a monoclinic system and P21 chirality space groups, and the chirality absolute configuration is determined by crystallography Flack parameter being 0.08(6); the unit cell size is shown in the specification, wherein beta is 95.817(4) degrees, and V is 2880.1(11). The characteristic peak in an X-ray powder diffraction pattern (Cu-Kalpha) is displayed at 2thea being 6.70 degrees, 10.12 degrees, 12.40 degrees, 13.36 degrees, 13.68 degrees, 17.04 degrees, 22.46 degrees and 24.16 degrees. The invention further provides a preparation method and application of the levamlodipine besylate crystal. The levamlodipine besylate crystal has the specific crystal form and the amount of crystal water and specific crystallography main parameters and the exact atom spatial position, the solubleness and stability of existing levamlodipine besylate are improved, the stability and bioavailability of the levamlodipine besylate tablet can be improved, preparation is easy, the cost is low, and the obtained crystal is regular in form, uniform in particle size and suitable for large-scale application and popularization.

The invention discloses a visible light catalyst BiVO4 and a preparation method thereof. The BiVO4 is powder, the crystalline phase is monoclinic crystal serial scheelite structure, and the feature thereof is in a three-dimensional connected pore channel structure. In the preparation method, ethanediol is utilized as solvent, and bismuth salt and vanadium salt are respectively used as a Bi source and a V source for preparing the three-dimensional connected pore channel structural BiVO4. The preparation method is as follows: dissolving bismuth salt and vanadium salt into ethanediol according to the proportion that Bi / V equals to 1:0.5-1:2 to prepare solution the Bi ion concentration of which is 0.05-0.5mol.L<-1>; forming even settled solution, and then transferring the settled solution to a constant-temperature water bath tank of 50-90 DEG C to preserve heat for 2-10 days; and after obtaining flocks, centrifuging, washing, drying and finally calcining obtained powder at the temperature of 350-600 DEG C for 1-3h in air environment. In the invention, no surfactant is utilized, and the catalyst with novel structure and very large specific surface area is obtained after simple heat preservation in the water bath tank and later-stage low temperature heat treatment. The catalyst has smaller particles and higher photocatalysis activity, thus being applied to degrading organic pollutants by visible light catalyst.

An electrode active material comprising in major proportions a monoclinic titanium-niobium composite oxide represented by the formula TiNbxO(2+5x / 2), wherein X is from 1.90 or more to less than 2.00.

The invention discloses a sofosbuvir monocrystal M and a preparation method and applications of the sofosbuvir monocrystal M. The sofosbuvir monocrystal prepared according to the preparation method disclosed by the invention belongs to a monoclinic system, and the space group is P21; the unit cell parameters are as follows: a=13.816 (3) A, b=5.973 (2) A, c=17.666 (4) A, and Beta=108.96 (3); the unit cell volume is 1378.7 (3) A3, and the number Z of molecules in a unit cell is 2. Solvents selected in the sofosbuvir monocrystal M disclosed by the invention are methylene chloride, chloroform, ethanol, isopropanol, acetonitrile, and C3-C7 alkyl cyanoacetate or C3-C7 dialkyl carbonate or C3-C7 dialkyl oxalate, and the like, and the sofosbuvir monocrystal is prepared by using a solvent evaporation method. The sofosbuvir monocrystal prepared according to the preparation method disclosed by the invention has good stability.